DepYmed

Executive Summary

DepYmed is a privately held biotechnology company headquartered in Cambridge, Massachusetts, founded in 2018. The company is developing novel small molecule therapeutics, primarily focusing on potent inhibitors of the enzyme PTP1B for diseases including Rett Syndrome, oncology, and Wilson Disease. Additionally, DepYmed has a portfolio of small molecules with copper chelating properties for Wilson Disease and cancer. The company is currently in Phase 1 stage with its lead program targeting Rett Syndrome, a rare neurodevelopmental disorder with no disease-modifying treatments approved. DepYmed's PTP1B inhibition approach has potential to address multiple indications, and its copper chelator platform offers differentiation in Wilson Disease. With limited public information and early-stage clinical development, the company represents a high-risk, high-reward opportunity in precision therapeutics.

Upcoming Catalysts (preview)

• TBDInitiation of Phase 1 clinical trial for PTP1B inhibitor in Rett Syndrome60% success
• TBDPreclinical data release for oncology PTP1B program50% success
• TBDPotential partnership or licensing deal for Wilson Disease copper chelator program40% success